TWI860849B - Sstr4促效劑鹽 - Google Patents

Sstr4促效劑鹽 Download PDF

Info

Publication number
TWI860849B
TWI860849B TW112136333A TW112136333A TWI860849B TW I860849 B TWI860849 B TW I860849B TW 112136333 A TW112136333 A TW 112136333A TW 112136333 A TW112136333 A TW 112136333A TW I860849 B TWI860849 B TW I860849B
Authority
TW
Taiwan
Prior art keywords
compound
formula
methyl
oxy
azabicyclo
Prior art date
Application number
TW112136333A
Other languages
English (en)
Chinese (zh)
Other versions
TW202400577A (zh
Inventor
大衛 安德魯 寇特
大衛 麥可 雷米克
Original Assignee
美商美國禮來大藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商美國禮來大藥廠 filed Critical 美商美國禮來大藥廠
Publication of TW202400577A publication Critical patent/TW202400577A/zh
Application granted granted Critical
Publication of TWI860849B publication Critical patent/TWI860849B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112136333A 2021-09-14 2022-09-13 Sstr4促效劑鹽 TWI860849B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163243785P 2021-09-14 2021-09-14
US63/243,785 2021-09-14

Publications (2)

Publication Number Publication Date
TW202400577A TW202400577A (zh) 2024-01-01
TWI860849B true TWI860849B (zh) 2024-11-01

Family

ID=83508479

Family Applications (3)

Application Number Title Priority Date Filing Date
TW112136333A TWI860849B (zh) 2021-09-14 2022-09-13 Sstr4促效劑鹽
TW111134517A TWI822326B (zh) 2021-09-14 2022-09-13 Sstr4促效劑鹽
TW113126835A TW202444703A (zh) 2021-09-14 2022-09-13 Sstr4促效劑鹽

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW111134517A TWI822326B (zh) 2021-09-14 2022-09-13 Sstr4促效劑鹽
TW113126835A TW202444703A (zh) 2021-09-14 2022-09-13 Sstr4促效劑鹽

Country Status (19)

Country Link
US (2) US11834435B2 (https=)
EP (1) EP4402136A1 (https=)
JP (2) JP2024533482A (https=)
KR (1) KR20240056751A (https=)
CN (1) CN117940413A (https=)
AR (1) AR127055A1 (https=)
AU (1) AU2022348561B2 (https=)
CA (1) CA3231451A1 (https=)
CL (2) CL2024000683A1 (https=)
CO (1) CO2024003038A2 (https=)
CR (1) CR20240118A (https=)
DO (1) DOP2024000050A (https=)
EC (1) ECSP24020256A (https=)
IL (1) IL311251A (https=)
JO (1) JOP20240053A1 (https=)
MX (1) MX2024003119A (https=)
PE (1) PE20240885A1 (https=)
TW (3) TWI860849B (https=)
WO (1) WO2023044326A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI860849B (zh) * 2021-09-14 2024-11-01 美商美國禮來大藥廠 Sstr4促效劑鹽
AU2024236692A1 (en) * 2023-03-10 2025-10-16 Eli Lilly And Company Methods for the preparation and dose regimens for use of sstr4 agonists and salts thereof
WO2025096300A1 (en) * 2023-10-30 2025-05-08 Eli Lilly And Company Novel methods for the preparation of 3-azabicylco[3.1,0]hexane-6-carboxamide derivatives
TW202600537A (zh) 2024-03-11 2026-01-01 美商美國禮來大藥廠 Ｓｓｔｒ４促效劑化合物及其組合物
GB202408483D0 (en) 2024-06-13 2024-07-31 Maxion Therapeutics Ltd Receptor agonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201536741A (zh) * 2013-05-17 2015-10-01 Boehringer Ingelheim Int 新穎生長抑制素受體亞型４（ｓｓｔｒ４）促效劑

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159941A (en) 1996-05-14 2000-12-12 Novo Nordisk A/S Use of somatostatin agonists and antagonists for treating diseases related to the eye
US6355613B1 (en) 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
US6063796A (en) 1997-04-04 2000-05-16 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
EP1565436B1 (en) 2002-11-27 2012-04-25 Incyte Corporation 3-aminopyrrolidine derivatives as modulators of chemokine receptors
FI20031454A0 (fi) 2003-10-06 2003-10-06 Juvantia Pharma Ltd Oy Selektiivisiä somatostatiinireseptori 1 ja/tai 4 -agonisteja ja -antagonisteja
US20100004339A1 (en) 2003-10-06 2010-01-07 Oy Juvantia Pharma Ltd. Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists
RS20060190A (sr) 2003-10-14 2008-08-07 Pfizer Products Inc., Biciklični /3.1.0/ derivati kao inhibitori transportera glicina
WO2007029086A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Derivatives of 3-azabicyclo[3.1.0]hexane as dipeptidyl peptidase-iv inhibitors
GB0616574D0 (en) 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds
CA2672373C (en) 2006-12-19 2011-08-30 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
CA2729767A1 (en) 2008-07-07 2010-01-14 Fasgen, Inc. Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same
WO2010059922A1 (en) 2008-11-21 2010-05-27 Ligand Pharmaceuticals Incorporated Pyrrolidine carboxamide compounds
US8835472B2 (en) 2010-09-02 2014-09-16 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
BR112013007566A2 (pt) 2010-09-28 2016-08-02 Panacea Biotec Ltd novos compostos bicíclicos
EP2685828A4 (en) 2011-03-17 2014-08-13 Merck Sharp & Dohme SUBSTITUTED 3-AZABICYCLO [3,1,0-] HEXAN DERIVATIVES AS CCR2 ANTAGONISTS
CN102675290B (zh) 2011-03-18 2014-11-12 山东亨利医药科技有限责任公司 含有并环的二氢吡唑类化合物
KR101556318B1 (ko) 2013-05-15 2015-10-01 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 6-피라졸일아미도-3-치환된 아자바이사이클로[3.1.0]헥산 유도체
WO2016075239A1 (en) 2014-11-14 2016-05-19 Boehringer Ingelheim International Gmbh Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (sstr4) agonists
BR112017009595A2 (pt) 2014-11-14 2017-12-19 Boehringer Ingelheim Int morfolina e 1,4-oxazepano amidas como agonistas do subtipo de receptor de somatostatina 4 (sstr4)
JP7774312B2 (ja) 2020-05-21 2025-11-21 クワンチョウ フェルミオン テクノロジー カンパニー リミテッド 縮合環化合物、それらの製造方法、医薬組成物、およびそれらの使用
WO2021233428A1 (zh) 2020-05-21 2021-11-25 广州费米子科技有限责任公司 含氮饱和杂环化合物及其制备方法、药物组合物和应用
WO2022012534A1 (zh) 2020-07-13 2022-01-20 广州费米子科技有限责任公司 含氮杂环化合物、药物组合物和应用
TWI860849B (zh) * 2021-09-14 2024-11-01 美商美國禮來大藥廠 Sstr4促效劑鹽

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201536741A (zh) * 2013-05-17 2015-10-01 Boehringer Ingelheim Int 新穎生長抑制素受體亞型４（ｓｓｔｒ４）促效劑

Also Published As

Publication number Publication date
CN117940413A (zh) 2024-04-26
MX2024003119A (es) 2024-04-09
ECSP24020256A (es) 2024-04-30
TWI822326B (zh) 2023-11-11
TW202400577A (zh) 2024-01-01
JP2024533482A (ja) 2024-09-12
AU2022348561B2 (en) 2025-05-22
IL311251A (en) 2024-05-01
US12486249B2 (en) 2025-12-02
AR127055A1 (es) 2023-12-13
EP4402136A1 (en) 2024-07-24
JP2025111617A (ja) 2025-07-30
CA3231451A1 (en) 2023-03-23
TW202444703A (zh) 2024-11-16
CR20240118A (es) 2024-04-25
CO2024003038A2 (es) 2024-04-18
TW202330492A (zh) 2023-08-01
CL2025002158A1 (es) 2025-11-07
WO2023044326A1 (en) 2023-03-23
PE20240885A1 (es) 2024-04-24
US11834435B2 (en) 2023-12-05
JOP20240053A1 (ar) 2024-03-12
CL2024000683A1 (es) 2024-08-23
KR20240056751A (ko) 2024-04-30
DOP2024000050A (es) 2024-04-30
AU2022348561A1 (en) 2024-03-14
US20230099116A1 (en) 2023-03-30
US20240067628A1 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
TWI860849B (zh) Sstr4促效劑鹽
EP3788045B1 (en) Rip1 inhibitory compounds and methods for making and using the same
EP3331879B1 (en) Benzazole compounds and methods for making and using the compounds
WO2019006126A1 (en) KINASE INHIBITORS AND METHODS OF MAKING AND USING THEM
WO2023124824A1 (zh) 一种glp-1激动剂的盐及其晶型和在医药上的应用
CN111132984A (zh) 凋亡信号调节激酶1抑制剂的盐及其晶型
TW202110833A (zh) 新穎環狀緩激肽b2受體拮抗劑
WO2023130878A1 (zh) 一种glp-1激动剂盐及其晶型及在医药上的应用
WO2021100019A1 (en) Prodrugs of abiraterone
CN110204552A (zh) 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途
WO2023138681A1 (zh) 含氮并环类衍生物抑制剂的酸式盐或晶型及其制备方法和应用
JP2024530315A (ja) Ｂｃｌ－２阻害剤の固体形態、それらの調製方法及び使用方法
CN114072406A (zh) Flna-结合化合物及其盐酸盐的固体多晶型物
JP7707406B2 (ja) Ｍｏｒ受容体アゴニストの薬学的に許容できる塩、その多形体及びその使用
EA050624B1 (ru) Соли агониста sstr4
JP6961348B2 (ja) 置換されたイミダゾピリジニル−アミノピリジン化合物の塩および多型
TW202311267A (zh) 咪唑烷酮類化合物的多晶型物、包含其的藥物組合物、其製備方法及其應用
HK40111611A (zh) 含氮并环类衍生物抑制剂的酸式盐或晶型及其制备方法和应用
HK40111611B (zh) 含氮并环类衍生物抑制剂的酸式盐或晶型及其制备方法和应用
TW202110429A (zh) 環狀緩激肽b2受體拮抗劑
HK40064763A (en) Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
HK40041257A (en) Rip1 inhibitory compounds and methods for making and using the same
HK40041257B (en) Rip1 inhibitory compounds and methods for making and using the same
NZ629884B (en) SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO[2,3-b]PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF